Developing antimicrobial foam dressings that fill deep, complex wounds
Deep, complex wounds contain irregular cavities that flat dressings struggle to reach. Wound fluid can harbour harmful bacteria, while delayed evacuation after battlefield injuries leaves wounds exposed to contamination and makes infection control harder.
AleSac is developing an injectable silicone foam that expands to fill deep wounds, absorbs wound fluid and inhibits bacterial growth. It targets protection of combat wounds during evacuation and dressings for chronic wounds.
What stands out about AleSac
DTU Science Park reports that AleSac's foam kills multidrug-resistant bacteria in under 120 minutes in vitro.
Accepted into the US BioLab CATALYST medtech accelerator, with access to regulatory expertise and an investor network.
Developed a physical foam-delivery prototype using a large syringe in a caulking gun, enabling practical user feedback.
Innoexplorer grant support helped AleSac's originating work mature the foam technology and develop a physical prototype.
Creadis supports AleSac through a pro bono collaboration arranged via MedTech Growth, advising on product development.
Co-founder Anne Ladegaard Skov is a DTU professor and department head whose polymer research underpins the wound foam.
CEO and co-founder Stina Bjerg Nielsen previously founded Glysious.
Co-founder Anne Ladegaard Skov received DTU's 2026 Innovation Award, recognising translation of research into innovation.
Co-founder Stina Bjerg Nielsen completed the Maersk World Class Leadership Programme at Harvard Business School Executive Education in 2013.
Completed DTU Science Park’s ten-month MedTech Growth 2025 accelerator, covering regulatory strategy, fundraising and market access.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.